Scherbeijn, S.M.J.

hbsag patient peg-ifn decline hbsag decline hbeag hepatitis level baseline serum hbeag-negative hbeag-negative patients hbeag-positive patients therapy study hbeag-positive hbeag loss treatment hepatitis b group 48 weeks week 48 hbsag levels etv therapy hbv dna levels hepatology 2010 vol antigen hepatology hbv dna serum hbsag levels signi monotherapy serum hbsag surface peginterferon hbeag-negative population reijnders jgp response entecavir peg-ifn group factor population genotype cccdna etv monotherapy treatment groups etv-treated patients reduction article treatment regimen kinetic analysis virus hepatitis b virus table etv-treated alt >2 uln ficant serum hbv dna baseline factors erasmus mc p <0.001 <0.001 peg-ifn therapy etv group journal signi ficantly clearance reijnder hepatol regimen liver baltimore result assay rotterdam hbv genotypes gastroenterology lamivudine peginterferon alfa -2a